ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, San Diego
Melbourne, Australia 18 March 2026 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April […]